Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Buy
57
TYRA Quote, Financials, Valuation and Earnings
Last price:
$25.46
Seasonality move
:
13.33%
Day range:
$24.88 - $26.17
52-week range:
$6.42 - $26.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.85x
Volume:
346.9K
Avg. volume:
575.5K
1-year change:
81.02%
Market cap:
$1.4B
Revenue:
--
EPS (TTM):
-$1.88
Analysts' Opinion
-
Consensus RatingTyra Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $33.00, Tyra Biosciences, Inc. has an estimated upside of 29.56% from its current price of $25.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $28.00 representing 100% downside risk from its current price of $25.47.
Fair Value
-
According to the consensus of 7 analysts, Tyra Biosciences, Inc. has 29.56% upside to fair value with a price target of $33.00 per share.
TYRA vs. S&P 500
-
Over the past 5 trading days, Tyra Biosciences, Inc. has overperformed the S&P 500 by 0.22% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Tyra Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Tyra Biosciences, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Tyra Biosciences, Inc. reported revenues of --.
Earnings Growth
-
Tyra Biosciences, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Tyra Biosciences, Inc. reported earnings per share of -$0.50.
Enterprise value:
1.1B
EV / Invested capital:
3.81x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.80x
EV / Free cash flow:
-11.96x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$558K
Return On Assets:
-32.61%
Net Income Margin (TTM):
--
Return On Equity:
-34.65%
Return On Invested Capital:
-34%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$333K | -$477K | -$558K | -$127K | -$131K | |
| Operating Income | -$69.3M | -$100.1M | -$126M | -$28.6M | -$32.9M | |
| EBITDA | -$69M | -$99.6M | -$125.4M | -$28.5M | -$32.8M | |
| Diluted EPS | -$1.39 | -$1.61 | -$1.88 | -$0.41 | -$0.50 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $313.5M | $267.5M | $224.6M | $365.6M | $281.2M | |
| Total Assets | $316M | $276M | $238.4M | $380.6M | $301.9M | |
| Current Liabilities | $4.8M | $5.5M | $10.1M | $12.4M | $15.9M | |
| Total Liabilities | $6.2M | $8.2M | $16.2M | $18.3M | $21.3M | |
| Total Equity | $309.7M | $267.8M | $222.2M | $362.3M | $280.5M | |
| Total Debt | $1M | $2.5M | $6M | $5.9M | $5.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.6M | -$63.7M | -$91.1M | -$17.9M | -$22.4M | |
| Cash From Investing | -$188K | -$249.8M | $45M | $21.6M | -$14.8M | |
| Cash From Financing | $1.2M | $201.8M | $4.1M | $743K | $647K | |
| Free Cash Flow | -$48.8M | -$65M | -$91.2M | -$18M | -$22.4M | |
TYRA
Sector
Market Cap
$1.4B
$27.9M
Price % of 52-Week High
96.69%
50.56%
Dividend Yield
0%
0%
Shareholder Yield
-0.54%
-1.55%
1-Year Price Total Return
81.02%
-17.49%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$24.97
200-day SMA
Buy
Level
$12.84
Bollinger Bands (100)
Buy
Level
11.27 - 20.31
Chaikin Money Flow
Buy
Level
1.6M
20-day SMA
Buy
Level
$23.23
Relative Strength Index (RSI14)
Buy
Level
70.27
ADX Line
Buy
Level
28.73
Williams %R
Sell
Level
-18.5935
50-day SMA
Buy
Level
$19.14
MACD (12, 26)
Buy
Level
7.10
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
1.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (18.4749)
Buy
CA Score
(Annual)
Level (-0.098)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (4.8768)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.
Stock Forecast FAQ
In the current month, TYRA has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TYRA average analyst price target in the past 3 months is $33.00.
-
Where Will Tyra Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Tyra Biosciences, Inc. share price will rise to $33.00 per share over the next 12 months.
-
What Do Analysts Say About Tyra Biosciences, Inc.?
Analysts are divided on their view about Tyra Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Tyra Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $28.00.
-
What Is Tyra Biosciences, Inc.'s Price Target?
The price target for Tyra Biosciences, Inc. over the next 1-year time period is forecast to be $33.00 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TYRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Tyra Biosciences, Inc. is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TYRA?
You can purchase shares of Tyra Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Tyra Biosciences, Inc. shares.
-
What Is The Tyra Biosciences, Inc. Share Price Today?
Tyra Biosciences, Inc. was last trading at $25.46 per share. This represents the most recent stock quote for Tyra Biosciences, Inc.. Yesterday, Tyra Biosciences, Inc. closed at $25.47 per share.
-
How To Buy Tyra Biosciences, Inc. Stock Online?
In order to purchase Tyra Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TYRA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TYRA
Sector
P/E ratio
--
23.75x
PEG ratio
-0.80x
-0.01x
P/B ratio
4.85x
1.81x
Price / LTM sales
--
1.59x
Growth Metrics
TYRA
Sector
Revenue growth
--
4.6%
Earnings growth
-22.73%
10.88%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.51
-$0.21
Profitability
TYRA
Sector
Profitability FY 2024
-$519K
$3.6M
Return on invested capital
-34%
-31.84%
Return on assets
-32.61%
-27.96%
Return on equity
-34.65%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
4
Balance Sheet
TYRA
Sector
Total cash
$274.9M
$26.3M
Short term investments
$249.5M
$25.7M
Total assets
$365.1M
$76.9M
Long term debt
$5.5M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 27.03% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is up 18.01% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 18.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
